-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Professor Ole Schmeltz Søgaard called the results of the new study an important step in
the search for a cure for AIDS.
For about 40 years, scientists around the world have been unsuccessful in finding a cure for AIDS, but now a team of researchers from Aarhus University and Aarhus University Hospital has clearly found an important factor
in it.
Dr.
Ole Schmeltz Søgaard, Professor of Translational Virus Studies at Aarhus University, is the corresponding author
of the article, which has just been published in the journal Nature Medicine.
"This study is one of the first to be conducted in humans, and we demonstrate a way to strengthen the body's own ability to fight HIV – even when standard treatment is suspended today
.
" Therefore, we see this study as an important step
towards a cure.
”
The study was conducted
in close collaboration with researchers from the UK, USA, Spain and Canada.
While no cure or vaccine to prevent HIV has been found, standard treatments today are highly effective
in controlling the disease.
Today, people living with HIV can receive so-called antiretroviral therapy, which suppresses the amount of virus in the blood and partially restores the immune system
.
However, if standard treatment is stopped, the amount of virus in the blood rises to the level before standard treatment began within a few weeks – regardless of whether the patient's treatment course is 10 or 20 years
.
That's because HIV is hidden in the genomes of some of the body's immune cells, which are targeted in a research project led by Denmark
.
In the study, researchers looked at the effects
of two experimental drugs on people who had recently been diagnosed with HIV.
Study participants from Denmark and the United Kingdom were randomly divided into four groups, all of whom received standard treatment
.
Some of them also take anti-HIV monoclonal antibodies (anti-HIV monoclonal antibodies that may eliminate infected cells and boost the immune system), drugs designed to prevent the virus from hiding in
the body's immune cells.
One group received standard treatment but did not use experimental drugs, while the last group received standard treatment and a combination
of two experimental drugs.
The results of this study are very encouraging, with Dr Jesper Damsgaard Gunst from Aarhus University Hospital being the lead author and another major driver of
the trial.
"Our study shows that newly diagnosed people with HIV who receive monoclonal antibodies and conventional drugs at the same time as treatment have a faster decline in virus numbers and develop better immunity to HIV
," he explains.
If they stop taking their regular medications, their immune system can partially or completely suppress the virus
.
”
The theory behind the experiment is that monoclonal antibodies help the immune system recognize and kill infected cells
.
In addition, these antibodies bind to large complexes of viruses that enter the lymph nodes, where they stimulate certain immune cells to develop immunity to HIV
.
In this way, the human body may be able to control the spread of the virus and "protect" itself from harm
caused by HIV infection.
Previous investigational drug clinical trials have not shown any significant effect
on a patient's HIV immunity or the ability of the immune system to suppress infection if standard treatment is discontinued.
However, the authors stress that despite the remarkable results, there is still some way to go
before we see a cure for HIV.
First, researchers need to find a way to optimize the treatment and amplify its effects
.
The Danish study has already attracted considerable attention abroad and increased interest
in testing newly diagnosed HIV-infected people.
In addition, the U.
S.
Department of Health recently allocated a large amount of money for research
in this area.
The Bill & Melinda Gates Foundation and a large research network have initiated follow-up to the Danish study in Africa
.
The research team is conducting a large study, which will be carried out across Europe, to optimize new experimental treatments
.
"We speculate that the optimized treatment will have a stronger effect on
the virus and the participants' immunity.
" In this way, we hope to enhance the immune system's ability to permanently suppress the
remaining virus.
”
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
